Search Results

Foundation Medicine, Inc., announced the U.S. launch of FoundationOne®RNA, a tissue-based RNA sequencing test for the detection of cancer-related fusions across 318 genes.

A team of investigators at City of Hope funded by the Prostate Cancer Foundation reports that patients with advanced prostate cancer can be safely treated with chimeric antigen receptor T cell therapy.

The Christopher & Dana Reeve Foundation and Kessler Foundation announced a pilot study to revolutionize bladder management for individuals with spinal cord injuries.

The Pediatric Brain Tumor Foundation announced the appointment of Ursula Burns and Jordan Wertlieb as inaugural members of the organization’s new Advisory Board.

The Kleine-Levin Syndrome Foundation announced the appointment of Jason Fisher as its first executive director.

The Biocodex Microbiota Foundation is announcing the 2024 open call for applications for its annual USA research grant.

The 2024 Global NF Conference, organized by the Children’s Tumor Foundation and the European NF Group, and hosted by Children’s Tumor Foundation Europe, is the foremost assembly defining the scientific and medical future of the genetic conditions neurofibromatosis and schwannomatosis.

Geneoscopy, Inc. will present research at the Crohn’s & Colitis Foundation’s IBD Innovate 2024 Conference in Cambridge, Mass., April 9-10.

Booz Allen Hamilton announced it was awarded a seven-year, $419 million contract with the National Science Foundation for Information Technology Mission Application Support.

Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. announced a partnership to develop Foundation Medicine’s tissue-based comprehensive genomic profiling test, FoundationOne®CDx, as a companion diagnostic for PMV Pharma’s rezatapopt, a first-in-class, investigational therapy for patients with locally advanced or metastatic solid tumors that have a TP53 Y220C mutation.